CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioVersys AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioVersys AG
c/o Technologiepark, Hochbergs
Phone: +41 615515120p:+41 615515120 BASEL, 4057  Switzerland Ticker: BIOVBIOV
Business Summary
BioVersys AG is a Switzerland based company engaged in the development of biopharmaceuticals. The Company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. Based on the identification and application of BV6481 the Company is expanding its screening and compound portfolio to nosocomial bacterial strains, such as Pseudomonas aeruginosa, Enterococcus faecium or Acinetobacter baumannii. Company has own pipeline that is focused on addressing the highest unmet medical needs in AMR. BioVersys AG focuses on the WHO and CDC highest priority pathogens and the indications with no satisfactory treatment options to date.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board SengChin Mah
Chief Executive Officer, Co-Founder, Director MarcGitzinger 12/1/2020
Chief Financial Officer HernanLevett 49
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 5,823,480 (As of 3/18/2025)
Stock Exchange: SWF


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025